Background
Methods
Patients
Study design
Snacks
Ingredients (g/230 g cookie/day) | Group A ISP + FO (n = 25) | Group B ISP + CO (n = 24) | Group C Control (n = 24) |
---|---|---|---|
ISP | 50 | 50 | 0 |
FO | 30 | 0 | 0 |
WF | 0 | 0 | 50 |
CO | 0 | 30 | 30 |
Sugar | 35 | 35 | 35 |
Medium-fat yogurt | 27 | 27 | 27 |
Medium-fat milk | 50 | 50 | 50 |
Rice flour | 20 | 20 | 20 |
Honey | 20 | 20 | 20 |
Concentrated date syrup | 19 | 19 | 19 |
Chocolate | 20 | 20 | 20 |
Pistachios | 10 | 10 | 10 |
Protein: | |||
Honey | 47.83 | 47.76 | 10.49 |
Chocolate | 48.89 | 48.46 | 11.54 |
Concentrated date syrup | 48.34 | 48.1 | 10.99 |
Kcal | |||
Honey | 788.4 | 783.9 | 762.7 |
Chocolate | 803.1 | 798.6 | 777.4 |
Concentrated date syrup | 785.8 | 781.3 | 760.1 |
Anthropometric measurements
Outcome measurements and systemic inflammatory response syndrome (SIRS)
Statistical analysis
Results
Participant characteristics
Variables | Group A ISP + FO (n = 25) | Group B ISP + CO (n = 24) | Group C Control (n = 24) | P valueb |
---|---|---|---|---|
TBSA (%) | 30.9 ± 1.93 | 32.5 ± 2.15 | 35.4 ± 2.09 | 0.28 |
Sex (M:F) | 18:7 | 19:5 | 17:7 | 0.73 |
Age (year) | 36.8 ± 2.56 | 31.6 ± 2.31 | 29.3 ± 1.78 | 0.09 |
Education (year) | 7.1 ± 0.87 | 8.0 ± 0.82 | 9.5 ± 0.71 | 0.12 |
Grafted patients (n) | 12 | 13 | 13 | 0.87 |
SIRS patients (n) | 11 | 11 | 10 | 0.70 |
SBP (mmHg) | 112.9 ± 3.26 | 116.8 ± 3.12 | 113.4 ± 3.08 | 0.64 |
DBP (mmHg) | 72.1 ± 2.40 | 73.2 ± 2.12 | 69.3 ± 1.69 | 0.36 |
Eating problems scorec | 1.1 ± 1.0 | 0.90 ± 0.8 | 1.4 ± 1.2 | 0.34 |
Energy intake (kcal/day) | 1659.4 ± 79.35 | 1637.3 ± 112.28 | 1600.9 ± 117.88 | 0.92 |
Protein intake (g/day) | 107.9 ± 6.43 | 103.8 ± 7.05 | 106.1 ± 8.16 | 0.92 |
Fat (g/day) | 64.4 ± 15.5 | 64.9 ± 17.2 | 61.7 ± 22.0 | 0.83 |
SFA (g/day) | 24.9 ± 6.2 | 23.9 ± 6.7 | 23.5 ± 7.4 | 0.77 |
MUFA (g/day) | 22.6 ± 5.6 | 23.3 ± 6.4 | 21.8 ± 6.4 | 0.79 |
PUFA (g/day) | 10.5 ± 3.2 | 11.5 ± 4.6 | 10.2 ± 5.7 | 0.63 |
Linolenic acid (g/day) | 0.32 ± 0.07 | 0.32 ± 0.10 | 0.30 ± 0.09 | 0.67 |
Effect of treatment on muscle catabolism, liver function, TG, cholesterol, and FBS indices
Variables | Group A ISP + FO (n = 25) | Group B ISP + CO (n = 24) | Group C Control (n = 24) | P valueb |
---|---|---|---|---|
Primary outcomes: | ||||
Nitrogen balance (g/day) | 2.19 ± 0.73c (1.83 to 2.5) | 2.4 ± 0.7c (2.04 to 2.72) | 2.3 ± 0.9d (1.89 to 2.7) | 0.008 |
Serum creatinine (mg/dl) | + 0.75 ± 0.24c (0.55 to 0.96) | + 0.64 ± 0.24c (0.49 to 0.80) | + 0.22 ± 0.09d (0.26 to 0.70) | 0.005 |
Secondary outcomes: | ||||
24 h UUN (g/day) | − 1.55 ± 5.8c (− 4.21 to 1.10) | − 1.10 ± 6.51c (− 4.07 to 1.86) | + 2.06 ± 5.25d (− 0.15 to 4.28) | 0.08 |
24 h Urine creatinine (g/day) | + 0.75 ± 0.24c (0.55 to 0.96) | + 0.64 ± 0.24c (0.50 to 0.80) | + 0.5 ± 0.2d (0.26 to 0.73) | 0.16 |
Weight (Kg) | − 1.71 ± 1.3c (0.55 to 0.96) | −3.01 ± 2.17c (0.55 to 0.96) | −6.00 ± 2.7d (0.55 to 0.96) | < 0.0001 |
BMI (Kg/m2) | − 0.55 ± 0.44c (0.55 to 0.96) | − 1.16 ± 1.00c (0.55 to 0.96) | − 2.14 ± 0.94d (0.55 to 0.96) | < 0.0001 |
TLC (%) | + 0.75 ± 0.24c (− 0.72 to 0.83) | + 0.64 ± 0.24c (− 1.36 to 0.72) | + 0.5 ± 0.2d (− 1.81 to − 0.11) | 0.16 |
Variables | Group A ISP + FO (n = 25) | Group B ISP + CO (n = 24) | Group C Control (n = 24) | P value |
---|---|---|---|---|
FBSb (mg/dL) | 1.93 ± 1.55c (0.0 to 3.8) | 3.15 ± 1.44c (0.85 to 5.44) | 3.28 ± 0.71c (2.54 to 4.03) | 0.58 |
TG (mg/dL) | −30.04 ± 64.40c (− 59.36 to − 0.73) | −3.28 ± 84.76c (− 41.86 to 35.29) | 1.58 ± 59.84c (− 23.68 to 26.85) | 0.28 |
Total cholesterol (mg/dL) | −44.38 ± 27.93c (− 57.09 to − 31.66) | −26.19 ± 48.44c (− 48.24 to − 4.13) | − 13.75 ± 51.80c (− 35.62 to 8.12) | 0.07 |
ALTb (IU/L) | 3.42 ± 1.09c (2.79 to 4.05) | 3.27 ± 1.47c (2.45 to 4.08) | 3.25 ± 0.83c (2.86 to 3.64) | 0.84 |
ASTb (IU/L) | 2.49 ± 1.26c (1.51 to 3.46) | 3.23 ± 0.84c (2.69 to 3.77) | 3.24 ± 1.18c (2.48 to 3.99) | 0.16 |
ALP (IU/L) | 57.76 ± 15.88c (24.63 to 90.8) | 56.17 ± 25.06c (30.87 to 90.46) | 63.70 ± 12.80c (37.22 to 90.19) | 0.95 |
Total protein (g/dL) | + 0.91 ± 0.22c (0.45 to 1.38) | + 0.89 ± 0.25c (0.37 to 1.4) | + 0.74 ± 0.27c (0.18 to 1.3) | 0.86 |
Total bilirubinb (mg/dL) | −2.57 ± 0.70c (− 3.31 to − 1.83) | −2.76 ± 0.52c (− 3.40 to − 2.11) | −2.93 ± 0.55c (− 3.40 to 2.11) | 0.10 |
Direct bilirubinb (mg/dL) | −2.04 ± 0.22c (− 2.14 to − 1.93) | −2.04 ± 0.20c (− 2.14 to − 1.95) | −2.07 ± 0.19c (− 2.15 to − 1.99) | 0.75 |
Effect of treatment on anemia markers
Variables | Group A ISP + FO (n = 25) | Group B ISP + CO (n = 24) | Group C Control (n = 24) | P value |
---|---|---|---|---|
RBC (106/μL) | −1.97 ± 0.23b (−2.46 to 1.47) | −2.22 ± 0.21b (− 2.68 to 1.76) | −2.44 ± 0.21b (− 2.88 to 2.00) | 0.58 |
WBC (103/μL) | − 44.38 ± 14.05b (− 8.59 to − 1.39) | −26.19 ± 18.49b (− 7.12 to 0.27) | −13.75 ± 12.21b (− 9.59 to − 0.58) | 0.79 |
Lymphocyte (%) | + 3.38 ± 3.00b (− 2.88 to 9.65) | −2.90 ± 2.50b (− 2.32 to 8.13) | −0.20 ± 2.01b (− 4.37 to 3.96) | 0.53 |
Hb (g/dL) | − 3.99 ± 0.58b (− 5.20 to − 2.78) | −4.47 ± 0.57b (− 5.68 to − 3.28) | −5.82 ± 0.55b (− 6.96 to − 4.67) | 0.06 |
HCT (%) | −15.46 ± 1.79b (− 19.21 to − 11.70) | −15.30 ± 1.77b (− 19.00 to − 11.60) | −18.50 ± 1.31b (− 21.22 to − 15.79) | 0.28 |
MCV (FL) | + 2.28 ± 1.09b (0.00 to 4.56) | + 0.92 ± 0.58b (0.29 to 2.14) | + 2.24 ± 0.83b (0.51 to 3.97) | 0.46 |
MCH (Pg) | + 0.80 ± 0.41b (− 0.05 to 1.67) | + 0.51 ± 0.24b (0.00 to 1.02) | + 0.71 ± 0.59b (− 0.51 to 1.94) | 0.90 |
MCHC (g/dL) | + 0.05 ± 0.37b (− 0.72 to 0.84) | −0.20 ± 0.43b (− 1.10 to 0.70) | −0.29 ± 0.21b (− 0.74 to 0.15) | 0.75 |